Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Citi
Johnson and Johnson
Dow
Accenture
Covington
UBS
Cipla
Express Scripts

Generated: December 16, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR VALSARTAN AND HYDROCHLOROTHIAZIDE

« Back to Dashboard

Clinical Trials for Valsartan And Hydrochlorothiazide

Trial ID Title Status Sponsor Phase Summary
NCT00168779 Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension Completed Boehringer Ingelheim Phase 4 The primary objective of this study is to compare the effectiveness of telmisartan 80 mg / hydrochlorothiazide 25 mg [Micardis HCT] to valsartan 160 mg / hydrochlorothiazide 25 mg [Diovan HCT] and placebo in the treatment of Stage 1 and Stage 2 hypertension.
NCT00170937 A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome Completed Novartis Phase 4 The metabolic syndrome is a classification for patients with a constellation of risk factors which may include abdominal obesity, hypertension, elevated blood lipids and sugar. Three or more of these factors together constitute the metabolic syndrome and place these patients at a greater risk for the development of diabetes and cardiovascular diseases. The purpose of this study is to determine whether two common drugs to lower blood pressure, whether used separately or in combination, have different effects on blood sugar levels in patients diagnosed with the metabolic syndrome.
NCT00170989 Valsartan/Hydrochlorothiazide Combination in Hypertensive Patients Not Controlled With Valsartan Alone Completed Novartis Phase 3 This study will test the effectiveness and safety of a combination treatment in patients whose blood pressure is not controlled with a single medication.
NCT00171015 VALORY Study of Valsartan/Hydrochlorizide for Patients Who do Not Respond Adequately to Olmesartan Medoxomil Completed Novartis Phase 3 To evaluate the efficacy of valsartan 160 mg/HCTZ 25 mg in patients not adequately responding to monotherapy with olmesartan medoxomil 40 mg or combination therapy with olmesartan medoxomil 20 mg plus HCTZ 12.5 mg by testing the hypothesis that valsartan 160 mg/HCTZ 25 mg significantly reduces the trough mean sitting diastolic blood pressure (MSDBP) after a 4-week treatment in the nonresponder population.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Valsartan And Hydrochlorothiazide

Condition Name

Condition Name for Valsartan And Hydrochlorothiazide
Intervention Trials
Hypertension 38
Healthy Normotensive Participants 2
Diabetes Mellitus, Type 2 2
METABOLIC SYNDROME 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Valsartan And Hydrochlorothiazide
Intervention Trials
Hypertension 37
Albuminuria 2
Metabolic Syndrome X 2
Diabetes Mellitus, Type 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Valsartan And Hydrochlorothiazide

Trials by Country

Trials by Country for Valsartan And Hydrochlorothiazide
Location Trials
United States 152
Switzerland 8
Canada 8
Germany 7
Taiwan 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Valsartan And Hydrochlorothiazide
Location Trials
New Jersey 10
California 7
Alabama 6
Texas 6
Oklahoma 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Valsartan And Hydrochlorothiazide

Clinical Trial Phase

Clinical Trial Phase for Valsartan And Hydrochlorothiazide
Clinical Trial Phase Trials
Phase 4 21
Phase 3 19
N/A 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Valsartan And Hydrochlorothiazide
Clinical Trial Phase Trials
Completed 40
Unknown status 1
Active, not recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Valsartan And Hydrochlorothiazide

Sponsor Name

Sponsor Name for Valsartan And Hydrochlorothiazide
Sponsor Trials
Novartis 26
Novartis Pharmaceuticals 3
Boehringer Ingelheim 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Valsartan And Hydrochlorothiazide
Sponsor Trials
Industry 37
Other 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Daiichi Sankyo
Harvard Business School
Johnson and Johnson
US Department of Justice
Federal Trade Commission
Colorcon
McKinsey
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.